论文部分内容阅读
目的探讨不同剂量的米非司酮治疗子宫肌瘤的临床效果对比。方法就该院在2014年1月-2015年12月收治的子宫肌瘤患者中,选择具有可比性的110例患者作为研究对象,将其随机分成观察组与对照组,每组55例,观察组给予患者12.5 mg/d剂量的米非司酮治疗,对照组给予患者25 mg/d剂量的米非司酮治疗,分别对比两组患者治疗后的各项激素水平、子宫肌瘤体积缩小情况、痛经改善率以及不良反应。结果两组患者治疗后的各项激素水平差异不明显,两组患者的子宫肌瘤体积在治疗后都有明显的缩小,观察组患者的痛经改善率明显低于对照组患者的痛经改善率,观察组患者的不良反应发生率明显少于对照组患者的不良反应发生率,P<0.05为差异具有统计学意义。结论小剂量的米非司酮治疗子宫肌瘤临床疗效确切,且不良反应发生率更低,安全性更高,值得临床的推广及应用。
Objective To investigate the clinical efficacy of different doses of mifepristone in the treatment of uterine fibroids. Methods A total of 110 patients with uterine fibroids who were admitted to our hospital from January 2014 to December 2015 were selected as the study subjects and randomly divided into observation group and control group with 55 cases in each group. Group were given 12.5 mg / d of mifepristone, while the control group was given 25 mg / d of mifepristone. The levels of hormones, contractions of uterine fibroids were compared between the two groups , Dysmenorrhea improvement rate and adverse reaction. Results There was no significant difference in the levels of hormones between the two groups after treatment. The volume of uterine fibroids in both groups was significantly reduced after treatment. The improvement rates of dysmenorrhea in observation group were significantly lower than those in control group, The incidence of adverse reactions in the observation group was significantly less than that in the control group, P <0.05 was considered statistically significant. Conclusion The low dose of mifepristone treatment of uterine fibroids clinical curative effect, and the incidence of adverse reactions lower, higher safety, it is worth the clinical promotion and application.